CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print February 20, 2008
CA Cancer J Clin 2008; 58:71-96
doi: 10.3322/CA.2007.0010
© 2008 American Cancer Society
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow All Versions of this Article:
CA.2007.0010v1
58/2/71    most recent
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.

Cancer Statistics, 2008

Ahmedin Jemal, DVM, PhD, Rebecca Siegel, MPH, Elizabeth Ward, PhD, Yongping Hao, PhD, Jiaquan Xu, MD*, Taylor Murray and Michael J. Thun, MD, MS

Dr. Jemal is Strategic Director, Cancer Surveillance, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Siegel is Manager, Surveillance Information Services, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Ward is Managing Director, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Hao is Senior Epidemiologist, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Xu is Epidemiologist, Mortality Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD.
Mr. Murray is Manager, Surveillance Data Systems, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Thun is Vice President, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.

Published online through CA First Look at http://CAonline.AmCancerSoc.org.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,437,180 new cancer cases and 565,650 deaths from cancer are projected to occur in the United States in 2008. Notable trends in cancer incidence and mortality include stabilization of incidence rates for all cancer sites combined in men from 1995 through 2004 and in women from 1999 through 2004 and a continued decrease in the cancer death rate since 1990 in men and since 1991 in women. Overall cancer death rates in 2004 compared with 1990 in men and 1991 in women decreased by 18.4% and 10.5%, respectively, resulting in the avoidance of over a half million deaths from cancer during this time interval. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. Although much progress has been made in reducing mortality rates, stabilizing incidence rates, and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 
Cancer is a major public health problem in the United States and many other parts of the world. Currently, one in 4 deaths in the United States is due to cancer. In this article, we provide an overview of cancer statistics, including updated incidence, mortality, and survival rates, and expected numbers of new cancer cases and deaths in 2008.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 
    Data Sources
Mortality data from 1930 to 2005 in the United States were obtained from the National Center for Health Statistics (NCHS).1 Incidence data for long-term trends (1975 to 2004), 5-year relative survival rates, and data on lifetime probability of developing cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, currently covering about 26% of the US population.2–5 Incidence data (1995 to 2004) for projecting new cancer cases were obtained from cancer registries that participate in the SEER program or the Centers for Disease Control and Prevention (CDC)’s National Program of Cancer Registries (NPCR) through the North American Association of Central Cancer Registries (NAACCR). State-specific incidence rates were abstracted from Cancer in North America (2000–2004) Volume One,6 based on data collected by cancer registries participating in the SEER program and NPCR. Population data were obtained from the US Census Bureau.7 Causes of death were coded and classified according to the International Classification of Diseases (ICD-8, ICD-9, and ICD-10).8–10 Cancer cases were classified according to the International Classification of Diseases for Oncology.11

    Estimated New Cancer Cases
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because complete cancer registration has not yet been achieved in some states. Furthermore, the most recent year for which incidence and mortality data are available lags 3 to 4 years behind the current year due to the time required for data collection and compilation. Estimated new cancer cases in the current year (2008) were projected using a spatio-temporal model12 based on incidence data from 1995 through 2004 from 41 states and the District of Columbia that met NAACCR’s high-quality data standard for incidence, covering about 85% of the US population. The method also considers geographic variations in socio-demographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, and accounts for expected delays in case reporting.

    Estimated Cancer Deaths
We used the state-space prediction method13 to estimate the number of cancer deaths expected to occur in the United States and in each state in the year 2008. Projections are based on underlying cause of death from death certificates as reported to the NCHS.1 This model projects the number of cancer deaths expected to occur in 2008 based on the number that occurred each year from 1969 to 2005 in the United States and in each state separately.

    Other Statistics
We provide mortality statistics for the leading causes of death as well as deaths from cancer in the year 2005. Causes of death for 2005 were coded and classified according to ICD-10.8 This report also provides updated statistics on trends in cancer incidence and mortality rates, the probability of developing cancer, and 5-year relative survival rates for selected cancer sites based on data from 1975 through 2004.3 All age-adjusted incidence and death rates are standardized to the 2000 US standard population and expressed per 100,000 population.

The long-term incidence rates and trends (1975 to 2004) are adjusted for delays in reporting where possible. Delayed reporting primarily affects the most recent 1 to 3 years of incidence data (in this case, 2002 to 2004), especially for cancers such as melanoma, leukemia, and prostate that are frequently diagnosed in outpatient settings. The National Cancer Institute has developed a method to account for expected reporting delays in SEER registries for all cancer sites combined and many specific cancer sites.14 Delay-adjusted rates provide a more accurate assessment of trends in the most recent years for which data are available.

We also provide estimates of the total number of cancer deaths avoided due to the reduction in age-standardized cancer death rates since 1991 in men and 1992 in women. We applied the age-specific cancer death rates in the peak year for the age-standardized cancer death rates (1990 for males and 1991 for females) to the corresponding age-specific populations in the subsequent years through 2004 to obtain the number of expected deaths in each calendar year if the death rates had not decreased. We then summed the difference between the number of expected and observed deaths in each age group and calendar year for men and women separately to obtain the total number of cancer deaths avoided over the 13- or 14-year interval.


   SELECTED FINDINGS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 
    Expected Numbers of New Cancer Cases
Table 1 presents estimates of the numbers of new cases of invasive cancer expected among men and women in the United States in 2008. The overall estimate of about 1.44 million new cases does not include carcinoma in situ of any site except urinary bladder, nor does it include basal cell and squamous cell cancers of the skin. More than 1 million cases of basal cell and squamous cell skin cancer, about 67,770 cases of breast carcinoma in situ, and 54,020 cases of in situ melanoma are expected to be newly diagnosed in 2008. The estimated numbers of new cancer cases for each state and selected cancer sites are shown in Table 2.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Estimated New Cancer Cases and Deaths by Sex, United States, 2008*

 

View this table:
[in this window]
[in a new window]

  		TABLE 2 Age-standardized Incidence Rates for All Cancers Combined, 2000 to 2004, and Estimated New Cases* for Selected Cancers by State, United States, 2008

 
Figure 1 indicates the most common cancers expected to occur in men and women in 2008. Among men, cancers of the prostate, lung and bronchus, and colon and rectum account for about 50% of all newly diagnosed cancers. Prostate cancer alone accounts for about 25% (186,320) of incident cases in men. Based on cases diagnosed between 1996 and 2003, an estimated 91% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which 5-year relative survival approaches 100%.


Figure 1
View larger version (31K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 1 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths, by Sex, United States, 2008.

*Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates are rounded to the nearest 10.

 
The 3 most commonly diagnosed types of cancer among women in 2008 will be cancers of the breast, lung and bronchus, and colon and rectum, accounting for about 50% of estimated cancer cases in women. Breast cancer alone is expected to account for 26% (182,460) of all new cancer cases among women.

    Expected Number of New Cancer Deaths
Table 1 also shows the expected number of deaths from cancer projected for 2008 for men, women, and both sexes combined. It is estimated that about 565,650 Americans will die from cancer, corresponding to over 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colon and rectum in men, and cancers of the lung and bronchus, breast, and colon and rectum in women continue to be the most common fatal cancers. These 4 cancers account for half of the total cancer deaths among men and women (Figure 1). Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987. Lung cancer is expected to account for 26% of all female cancer deaths in 2008. Table 3 provides the estimated number of cancer deaths in 2008 by state for selected cancer sites.


View this table:
[in this window]
[in a new window]

  		TABLE 3 Age-standardized Death Rates for All Cancers Combined, 2000 to 2004, and Estimated Deaths* from All Cancers Combined and Selected Sites by State, United States, 2008

 
    Regional Variations in Cancer Rates
Table 4 depicts cancer incidence for select cancer sites by state. For some sites, rates vary widely across states. For example, among the cancers listed in Table 4, the largest variations in the incidence rates, in proportionate terms, occurred in lung cancer in which rates (cases per 100,000 population) ranged from 40.3 in men and 20.9 in women in Utah to 137.9 in men and 74.9 in women in Kentucky. In contrast, the variation in female breast cancer incidence rates was small, ranging from 105.4 cases per 100,000 population in Mississippi to 142.2 cases in Washington. Factors that contribute to state variations in incidence rates include differences in the prevalence of risk factors, access to and utilization of early detection services, and completeness of reporting. For example, the state variation in lung cancer incidence rates primarily reflects differences in smoking prevalence. Utah ranks lowest in adult smoking prevalence and Kentucky highest.


View this table:
[in this window]
[in a new window]

  		TABLE 4 Cancer Incidence Rates* by Site and State, United States, 2000 to 2004

 
    Trends in Cancer Incidence and Mortality
Figures 2GoGoGo to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. Table 5 shows incidence and mortality patterns for all cancer sites and for the 4 most common cancer sites based on joinpoint analysis. Trends in incidence were adjusted for delayed reporting. Delay-adjusted cancer incidence rates were stable in males from 1995 to 2004 and in females from 1999 to 2004. Death rates for all cancer sites combined decreased by 2.6% per year in males and by 1.8% in females from 2002 to 2004 compared with declines of 1.5% per year in males from 1992 to 2002 and 0.8% per year in females from 1994 to 2002.


Figure 2
View larger version (20K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 2 Annual Age-adjusted Cancer Incidence and Death Rates* for All Sites by Sex, United States, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population. Incidence rates are adjusted for delays in reporting.

Source: Incidence—Surveillance, Epidemiology, and End Results (SEER) program, (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2004." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2007, based on the November 2006 SEER data submission. Mortality—US Mortality Data, 1960 to 2004, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 3
View larger version (27K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 3 Annual Age-adjusted Cancer Incidence Rates* for Selected Cancers by Sex, United States, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population and adjusted for delays in reporting.

Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2004." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2007, based on the November 2006 SEER data submission.

 

Figure 4
View larger version (23K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 4 Annual Age-adjusted Cancer Death Rates* Among Males for Selected Cancers, United States, 1930 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the lung and bronchus, colon and rectum, and liver are affected by these changes.

Source: US Mortality Data, 1960 to 2004, US Mortality Volumes, 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 5
View larger version (20K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 5 Annual Age-adjusted Cancer Death Rates* Among Females for Selected Cancers, United States, 1930 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

{dagger}Uterus includes uterine cervix and uterine corpus.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the uterus, ovary, lung and bronchus, and colon and rectum are affected by these changes.

Source: US Mortality Data, 1960 to 2004, US Mortality Volumes 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

View this table:
[in this window]
[in a new window]

  		TABLE 5 Trends in Cancer Incidence and Death Rates for Selected Cancers by Sex, United States, 1975 to 2004

 
Mortality rates have continued to decrease across all 4 major cancer sites in both men and women, except for female lung cancer, in which rates continued to increase by 0.2% per year from 1995 to 2004 (Table 5). The incidence trends are mixed, however. Lung cancer incidence rates are declining in men and plateauing in women after increasing for many decades. The lag in the temporal trend of lung cancer incidence rates in women compared with men reflects historical differences in cigarette smoking between men and women; cigarette smoking in women peaked about 20 years later than in men. Colorectal cancer incidence rates have decreased from 1998 through 2004 in both males and females. Female breast cancer incidence rates decreased by 3.5% per year from 2001 to 2004 after increasing since 1980, likely reflecting both delays in diagnosis due to a decrease in mammography utilization and declines in hormone replacement therapy use among postmenopausal women.15–16 Prostate cancer incidence rates have stabilized from 1995 through 2004 following a short-term rapid increase and subsequent decrease between 1988 and 1995; these trends are thought to reflect changes in utilization of prostate-specific antigen testing.17–18

Table 6 shows the contribution of individual cancer sites to the total decrease in overall cancer death rates. Death rates from all cancers combined peaked in 1990 for men and in 1991 for women. Between 1990/1991 and 2004, death rates from cancer decreased by 18.4% among men and by 10.5% among women. Among men, reductions in death rates from lung, prostate, and colorectal cancers account for nearly 80% of the total decrease in cancer death rates, while reductions in death rates from breast and colorectal cancers account for 60% of the decrease among women. Lung cancer in men and breast cancer in women alone account for nearly 40% of the sex-specific decreases in cancer death rates. The decrease in lung cancer death rates among men is due to reduction in tobacco use over the past 40 years, while the decrease in death rates for colorectal, female breast, and prostate cancer largely reflects improvements in early detection and treatment.18 Between 1990/1991 and 2004, death rates increased substantially for lung cancer in women and for liver and intrahepatic bile duct cancer in men.


View this table:
[in this window]
[in a new window]

  		TABLE 6 The Contribution of Indvidual Cancer Sites to the Decrease in Cancer Death Rates, 1990 to 2004

 
    Recorded Number of Deaths from Cancer in 2005
A total of 559,312 cancer deaths were recorded in the United States in 2005, the most recent year for which actual data are available, accounting for about 23% of all deaths (Table 7). Despite a decrease in age-standardized death rates, there were 5,424 more cancer deaths reported in 2005 than in 2004 (3,592 in men and 1,832 in women) (Table 8). This contrasts with the decrease in the total number of cancer deaths that occurred from 2002 to 2003 and 2003 to 2004, in part due to a larger decrease in the age-standardized death rates from 2002 to 2004 (about 2% per year) compared with 2004 to 2005 (about 1% per year). With respect to the 4 major cancer sites, colorectal cancer death rates decreased by about 6% from 2003 to 2004 compared with only about 3% from 2004 to 2005. The declines in death rates for cancers of the lung and bronchus and prostate in men and breast in women were similarly attenuated from 2004 to 2005.


View this table:
[in this window]
[in a new window]

  		TABLE 7 Fifteen Leading Causes of Death, United States, 2005

 

View this table:
[in this window]
[in a new window]

  		TABLE 8 Trends in the Recorded Number of Deaths for Selected Cancers by Sex, United States, 1990 to 2005.

 
Cancer is one of the 5 leading causes of death in all age groups among both males and females (Table 9). Cancer is the leading cause of death among women aged 40 to 79 years and among men aged 60 to 79 years. Cancer is the leading cause of death among men and women under age 85 years (Figure 6). A total of 475,848 people under age 85 years died from cancer in the United States in 2005 compared with 408,550 deaths from heart disease.


View this table:
[in this window]
[in a new window]

  		TABLE 9 Ten Leading Causes of Death by Age and Sex, United States, 2005

 

Figure 6
View larger version (18K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 6 Death Rates* for Cancer and Heart Disease for Ages Younger than 85 and 85 and Older, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

Source: US Mortality Data, 1960 to 2004, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 
Table 10 presents the number of deaths from the 5 most common cancer sites for males and females at various ages. Among males under age 40 years, leukemia is the most common fatal cancer, while cancer of the lung and bronchus predominates in men aged 40 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at age 20 to 59 years, and lung cancer ranks first at age 60 years and older.


View this table:
[in this window]
[in a new window]

  		TABLE 10 Reported Deaths for the Five Leading Cancer Sites by Age and Sex, United States, 2005

 
Figure 7 shows the total number of cancer deaths avoided since death rates began to decrease in 1991 in men and in 1992 in women. As a result, over a half million cancer deaths (408,400 in men and 136,100 in women) were averted during the time interval of 1991/1992 through 2004.


Figure 7
View larger version (16K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 7 Total Number of Cancer Deaths Avoided from 1991 to 2004 in Men and 1992 to 2004 in Women.

The blue line represents the actual number of cancer deaths recorded in each year, and the bold red line represents the expected number of cancer deaths if cancer mortality rates had remained the same since 1990/1991.

 

   CANCER OCCURRENCE BY RACE/ETHNICITY
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 
Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 11). For all cancer sites combined, African American men have a 19% higher incidence rate and a 37% higher death rate than White men, whereas African American women have a 6% lower incidence rate but a 17% higher death rate than White women. For the specific cancer sites listed in Table 11, incidence and death rates are consistently higher in African Americans than in Whites, except for cancers of the breast (incidence) and lung (incidence and mortality) among women and kidney (mortality) among both men and women. Factors known to contribute to racial disparities in mortality vary by cancer site and include differences in exposure to underlying risk factors (eg, historical smoking prevalence for lung cancer among men), access to high-quality regular screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment (for many cancers). The higher breast cancer incidence rates among Whites are thought to reflect a combination of factors that affect both diagnosis (such as more frequent mammography in White women) and the underlying factors that affect disease occurrence (such as later age at first birth and greater use of hormone replacement therapy among White compared with African American women).19


View this table:
[in this window]
[in a new window]

  		TABLE 11 Cancer Incidence and Death Rates* by Site, Race, and Ethnicity, United States, 2000 to 2004

 
Among other racial and ethnic groups, cancer incidence and death rates are lower than those in Whites and African Americans for all cancer sites combined and for the 4 most common cancer sites. However, incidence and death rates are generally higher in minority populations than in Whites for cancers of the uterine cervix, stomach, and liver. Stomach and liver cancer incidence and death rates are more than twice as high in Asian American/Pacific Islanders as in Whites, reflecting increased exposure to infectious agents such as Helicobacter pylori and hepatitis B and C.20 Kidney cancer mortality rates are the highest among American Indians/Alaska Natives, although obesity is the only factor known to contribute to this disparity.

Trends in cancer incidence can be adjusted for delayed reporting only in Whites and African Americans because long-term incidence data required for delay adjustment are not available for other racial and ethnic subgroups. From 1995 to 2004, incidence rates in males for all cancer sites combined (unadjusted for delayed reporting) decreased among all racial and ethnic groups except American Indian/Alaska Native men; among women, rates stabilized in all racial and ethnic groups during the same time period. In contrast, death rates from cancer significantly decreased in each racial and ethnic group, with larger decreases in men than in women.3

    Death Rates by Educational Attainment, Race, and Sex
Table 12 shows death rates for all cancers combined and the 4 major cancers by educational attainment among White and African American men and women aged 25 to 64 years in 2001.21 The death rate for all cancers combined among less-educated (≤12 years of education) compared with more-educated (>12 years of education) people was more than twice as high in men and about 40% higher in women. For specific cancer sites, the ratio of death rates in the less-educated compared with the more-educated group ranged from 1.16 for breast cancer among African American women to 3.36 for lung cancer among White men. For lung cancer in men and women and for colorectal cancer in men, the absolute difference in death rates between the less educated and more educated was larger than the difference between Whites and African Americans by sex at each level of educational attainment. Factors that contribute to higher death rates from cancer in less-educated men and women include higher prevalence of risk factors such as smoking and obesity and limited access to medical services.


View this table:
[in this window]
[in a new window]

  		TABLE 12 Cancer Death Rates* by Educational Attainment, Race, and Sex, United States, 2001

 
    Lifetime Probability of Developing Cancer
The lifetime probability of being diagnosed with an invasive cancer is higher for men (45%) than women (38%) (Table 13). However, because of the relatively early age of breast cancer onset, women have a slightly higher probability of developing cancer before age 60 years. It is noteworthy that these estimates are based on the average experience of the general population and may over- or underestimate individual risk because of differences in exposure and/or genetic susceptibility.


View this table:
[in this window]
[in a new window]

  		TABLE 13 Probability of Developing Invasive Cancers Within Selected Age Intervals by Sex, United States*

 
    Cancer Survival by Race
Compared with Whites, African American men and women have poorer survival once cancer is diagnosed. Five-year relative survival is lower in African Americans than in Whites within each stratum of stage of diagnosis for nearly every cancer site (Figure 8). These disparities may result from inequalities in access to and receipt of quality health care and/or from differences in comorbidities.18 As shown in Figure 9, African Americans are less likely than Whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and are more likely to be diagnosed with cancer at a regional or distant stage of disease. The extent to which factors other than stage at diagnosis contribute to the overall differential survival is unclear.22 However, some studies suggest that African Americans who receive cancer treatment and medical care similar to that of Whites experience similar outcomes.23


Figure 8
View larger version (39K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 8 Five-year Relative Survival Rates Among Patients Diagnosed with Selected Cancers by Race and Stage at Diagnosis, United States, 1996 to 2003.

* The rate for localized stage represents localized and regional stages combined.

{dagger}The standard error of the survival rate is between 5 and 10 percentage points.

Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Melbert D, Krapcho M, et al.3

 

Figure 9
View larger version (33K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 9 Distribution of Selected Cancers by Race and Stage at Diagnosis, United States, 1996 to 2003.

*The rate for localized stage represents localized and regional stages combined.

Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. For each cancer type, stage categories do not total 100% because sufficient information is not available to assign a stage to all cancer cases. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Melbert D, Krapcho M, et al.3

 
There have been notable improvements since 1975 in relative 5-year survival rates for many cancer sites and for all cancers combined (Table 14). This is true for both Whites and African Americans. Cancers for which survival has not improved substantially over the past 25 years include uterine corpus, cervix, larynx, lung, and pancreas. The improvement in survival reflects a combination of earlier diagnosis and improved treatments.


View this table:
[in this window]
[in a new window]

  		TABLE 14 Trends in 5-Year Relative Survival Rates* (%) by Race and Year of Diagnosis, United States, 1975 to 2003

 
Relative survival rates cannot be calculated for racial and ethnic populations other than Whites and African Americans because accurate life expectancies (the average number of years of life remaining for persons who have attained a given age) are not available. However, based on cause-specific survival rates of cancer patients diagnosed from 1992 to 2000 in SEER areas of the United States, all minority populations except Asian American/Pacific Islander women have a greater probability of dying from cancer within 5 years of diagnosis than non-Hispanic Whites, after accounting for differences in stage at diagnosis.18,24 For the 4 major cancer sites (prostate, female breast, lung and bronchus, and colon and rectum), minority populations are more likely to be diagnosed at distant stage compared with non-Hispanic Whites.24


   CANCER IN CHILDREN
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
LIMITATIONS
 REFERENCES
 
Cancer is the second most common cause of death among children between the age of 1 and 14 years in the United States, surpassed only by accidents (Table 15). Leukemia (particularly acute lymphocytic leukemia) is the most common cancer in children (aged 0 to 14 years), followed by cancer of the brain and other nervous system, neuroblastoma, renal (Wilms) tumors, and non-Hodgkin lymphoma.3 Over the past 25 years, there have been significant improvements in the 5-year relative survival rate for all of the major childhood cancers (Table 16). The 5-year relative survival rate among children for all cancer sites combined improved from 58% for patients diagnosed in 1975 to 1977 to 80% for those diagnosed in 1996 to 2003.3


View this table:
[in this window]
[in a new window]

  		TABLE 15 Fifteen leading Causes of Death Among Children Aged 1 to 14, United states, 2005

 

View this table:
[in this window]
[in a new window]

  		TABLE 16 Trends in Five-year Relative Survival Rates* (%) for Children Under Age 15, United States, 1975 to 2003

 

   LIMITATIONS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
REFERENCES
 
Estimates of the expected numbers of new cancer cases and cancer deaths should be interpreted cautiously. These estimates may vary considerably from year to year, particularly for less common cancers and in states with smaller populations. Estimates are also affected by changes in method. The introduction of a new method for projecting incident cancer cases beginning with the 2007 estimates substantially affected the estimates for a number of cancers, particularly leukemia and female breast (see Pickle et al12 for more detailed discussion). Not all changes in cancer trends are captured by modeling techniques. For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. The preferred data sources for tracking cancer trends are the age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER or NPCR, even though these data are 3 and 4 years old, respectively, by the time that they become available. Nevertheless, the American Cancer Society estimates of the number of new cancer cases and deaths in the current year provide reasonably accurate estimates of the burden of new cancer cases and deaths in the United States.


   Footnotes
 
* Disclaimer: The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention. Back


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS
 REFERENCES
 

  1. National Center for Health Statistics, Division of Vital Statistics, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed November 15, 2007.
  2. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2006 Sub (1973–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  3. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site, 2007.
  4. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2006 Sub (1992–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  5. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Public-Use, Nov 2006 Sub (2000–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  6. Wu XC, McLaughlin CC, Lake A, et al., eds. Cancer in North America, 2000–2004. Volume One: Incidence. Springfield, IL: North American Association of Central Cancer Registries, Inc.; 2007.
  7. US Census Bureau. Available at: http://www.census.gov. Accessed September 16, 2007.
  8. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 10th revision. Geneva, Switzerland: World Health Organization; 1992.
  9. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 9th revision. Geneva, Switzerland: World Health Organization; 1975.
  10. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 8th revision. Geneva, Switzerland: World Health Organization; 1967.
  11. Fritz A, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  12. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin 2007;57:30–42.
  13. Tiwari RC, Ghosh K, Jemal A, et al. A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin 2004;54:30–40.
  14. Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 2002;94:1537–1545.
  15. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
  16. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–1674.
  17. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119–2152.
  18. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.
  19. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342–355.
  20. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004;54:78–93.
  21. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 2007;99:1384–1394.
  22. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin 2002;52:326–341.
  23. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106–2113.
  24. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162:1985–1993.



This article has been cited by other articles:


Home page
 Am J Clin PatholHome page
C. O'Brien, L. D. True, C. S. Higano, B. L. S. Rademacher, M. Garzotto, and T. M. Beer
Histologic Changes Associated With Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients With High-Risk Prostate Cancer
Am J Clin Pathol, April 1, 2010; 133(4): 654 - 661.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Subramanian and R. Simon
Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
J Natl Cancer Inst, March 16, 2010; (2010) djq025v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. Henneke, S. Greschus, R. Savai, M. Korfei, P. Markart, P. Mahavadi, R. T. Schermuly, M. Wygrecka, J. Sturzebecher, W. Seeger, et al.
Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model
Am. J. Respir. Crit. Care Med., March 15, 2010; 181(6): 611 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. M. Thirukkumaran, M. J. Nodwell, K. Hirasawa, Z.-Q. Shi, R. Diaz, J. Luider, R. N. Johnston, P. A. Forsyth, A. M. Magliocco, P. Lee, et al.
Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
Cancer Res., March 15, 2010; 70(6): 2435 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Lin, B. Hutzen, M. Zuo, S. Ball, S. Deangelis, E. Foust, B. Pandit, M. A. Ihnat, S. S. Shenoy, S. Kulp, et al.
Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Cancer Res., March 15, 2010; 70(6): 2445 - 2454.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Bartholomeusz, A. M. Gonzalez-Angulo, A. Kazansky, S. Krishnamurthy, P. Liu, L. X. H. Yuan, F. Yamasaki, S. Liu, N. Hayashi, D. Zhang, et al.
PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
Clin. Cancer Res., March 15, 2010; 16(6): 1802 - 1811.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Gallagher, M. I. Milowsky, S. R. Gerst, N. Ishill, J. Riches, A. Regazzi, M. G. Boyle, A. Trout, A.-M. Flaherty, and D. F. Bajorin
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
J. Clin. Oncol., March 10, 2010; 28(8): 1373 - 1379.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
I. Mertens-Walker, C. Bolitho, R. C Baxter, and D. J Marsh
Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}
Endocr. Relat. Cancer, March 8, 2010; 17(2): 335 - 349.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
X. S. Chen, X. Q. Nie, C. M. Chen, J. Y. Wu, J. Wu, J. S. Lu, Z. M. Shao, Z. Z. Shen, and K. W. Shen
Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer
Ann. Onc., March 8, 2010; (2010) mdq041v1.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. A. Bradbury, D. Tu, L. Seymour, P. K. Isogai, L. Zhu, R. Ng, N. Mittmann, M.-S. Tsao, W. K. Evans, F. A. Shepherd, et al.
Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer
J Natl Cancer Inst, March 3, 2010; 102(5): 298 - 306.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Z. A. Rasheed, J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S.-M. Hong, J.-B. Koorstra, N. V. Rajeshkumar, X. He, et al.
Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
J Natl Cancer Inst, March 3, 2010; 102(5): 340 - 351.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
G. Hoff and J. A Dominitz
Contrasting US and European approaches to colorectal cancer screening: which is best?
Gut, March 1, 2010; 59(3): 407 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Pallante, R. Visone, C. M. Croce, and A. Fusco
Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas
Endocr. Relat. Cancer, March 1, 2010; 17(1): F91 - F104.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
R C M Simmen, J M P Pabona, M C Velarde, C Simmons, O Rahal, and F A Simmen
The emerging role of Kruppel-like factors in endocrine-responsive cancers of female reproductive tissues
J. Endocrinol., March 1, 2010; 204(3): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Amari, T. Ishida, M. Takeda, and N. Ohuchi
Capecitabine Monotherapy is Efficient and Safe in All Line Settings in Patients with Metastatic and Advanced Breast Cancer
Jpn. J. Clin. Oncol., March 1, 2010; 40(3): 188 - 193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Makhija, L. C. Amler, D. Glenn, F. R. Ueland, M. A. Gold, D. S. Dizon, V. Paton, C.-Y. Lin, T. Januario, K. Ng, et al.
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
J. Clin. Oncol., March 1, 2010; 28(7): 1215 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Hopkins, V. Fedirko, D. P. Jones, P. D. Terry, and R. M. Bostick
Antioxidant Micronutrients and Biomarkers of Oxidative Stress and Inflammation in Colorectal Adenoma Patients: Results from a Randomized, Controlled Clinical Trial
Cancer Epidemiol. Biomarkers Prev., March 1, 2010; 19(3): 850 - 858.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. B. McBride, B. Lebwohl, D. L. Hershman, and A. I. Neugut
Impact of Socioeconomic Status on Extent of Lymph Node Dissection for Colon Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2010; 19(3): 738 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. W. Rogers, M. A. Weinstock, A. R. Harris, M. R. Hinckley, S. R. Feldman, A. B. Fleischer, and B. M. Coldiron
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
Arch Dermatol, March 1, 2010; 146(3): 283 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. Kalkhoran, O. Milne, I. Zalaudek, S. Puig, J. Malvehy, J. W. Kelly, and A. A. Marghoob
Historical, Clinical, and Dermoscopic Characteristics of Thin Nodular Melanoma
Arch Dermatol, March 1, 2010; 146(3): 311 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cappuzzo, G. Tallini, G. Finocchiaro, R. S. Wilson, C. Ligorio, L. Giordano, L. Toschi, M. Incarbone, R. Cavina, L. Terracciano, et al.
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients
Ann. Onc., March 1, 2010; 21(3): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M.-L. Zhu and N. Kyprianou
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells
FASEB J, March 1, 2010; 24(3): 769 - 777.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Starlard-Davenport, V. P. Tryndyak, S. R. James, A. R. Karpf, J. R. Latendresse, F. A. Beland, and I. P. Pogribny
Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats
Carcinogenesis, March 1, 2010; 31(3): 376 - 381.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, A. J. Cucchiara, J. Q. Yu, and A. Alavi
The Effect of Age, Menopausal State, and Breast Density on 18F-FDG Uptake in Normal Glandular Breast Tissue
J. Nucl. Med., March 1, 2010; 51(3): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. Kligerman and G. Abbott
A Radiologic Review of the New TNM Classification for Lung Cancer
Am. J. Roentgenol., March 1, 2010; 194(3): 562 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
T. Franiel, L. Ludemann, B. Rudolph, E. Lutterbeck, B. Hamm, and D. Beyersdorff
Differentiation of Prostate Cancer From Normal Prostate Tissue: Role of Hotspots in Pharmacokinetic MRI and Histologic Evaluation
Am. J. Roentgenol., March 1, 2010; 194(3): 675 - 681.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Tanaka, M. Nakao, T. Ioka, R. Takakura, Y. Takano, H. Tsukuma, H. Uehara, R. Suzuki, and J. Fukuda
Slight Dilatation of the Main Pancreatic Duct and Presence of Pancreatic Cysts as Predictive Signs of Pancreatic Cancer: A Prospective Study
Radiology, March 1, 2010; 254(3): 965 - 972.
[Abstract] [Full Text] [PDF]

Home page
 J Gerontol A Biol Sci Med SciHome page
S. M. Koroukian, F. Xu, P. M. Bakaki, M. Diaz-Insua, T. P. Towe, and C. Owusu
Comorbidities, Functional Limitations, and Geriatric Syndromes in Relation to Treatment and Survival Patterns Among Elders With Colorectal Cancer
J Gerontol A Biol Sci Med Sci, March 1, 2010; 65A(3): 322 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Hirata, Y. Hinoda, K. Ueno, S. Majid, S. Saini, and R. Dahiya
Role of Secreted Frizzled-Related Protein 3 in Human Renal Cell Carcinoma
Cancer Res., March 1, 2010; 70(5): 1896 - 1905.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Iorio, A. Ricci, M. Bagnoli, M. E. Pisanu, G. Castellano, M. Di Vito, E. Venturini, K. Glunde, Z. M. Bhujwalla, D. Mezzanzanica, et al.
Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells
Cancer Res., March 1, 2010; 70(5): 2126 - 2135.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Beck, H. B. Urnovitz, W. M. Mitchell, and E. Schutz
Next Generation Sequencing of Serum Circulating Nucleic Acids from Patients with Invasive Ductal Breast Cancer Reveals Differences to Healthy and Nonmalignant Controls
Mol. Cancer Res., March 1, 2010; 8(3): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. D. Sharma, S. M. Meeran, and S. K. Katiyar
Proanthocyanidins Inhibit In vitro and In vivo Growth of Human Non-Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors
Mol. Cancer Ther., March 1, 2010; 9(3): 569 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Mimeault, S. L. Johansson, J.-P. Henichart, P. Depreux, and S. K. Batra
Cytotoxic Effects Induced by Docetaxel, Gefitinib, and Cyclopamine on Side Population and Nonside Population Cell Fractions from Human Invasive Prostate Cancer Cells
Mol. Cancer Ther., March 1, 2010; 9(3): 617 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
A. S. McCampbell, H. A. Harris, J. S. Crabtree, R. C. Winneker, C. L. Walker, and R. R. Broaddus
Loss of Inhibitory Insulin Receptor Substrate-1 Phosphorylation Is an Early Event in Mammalian Target of Rapamycin-Dependent Endometrial Hyperplasia and Carcinoma
Cancer Prevention Research, March 1, 2010; 3(3): 290 - 300.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
N. P. Evans, S. A. Misyak, E. M. Schmelz, A. J. Guri, R. Hontecillas, and J. Bassaganya-Riera
Conjugated Linoleic Acid Ameliorates Inflammation-Induced Colorectal Cancer in Mice through Activation of PPAR{gamma}
J. Nutr., March 1, 2010; 140(3): 515 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Tseng-Rogenski, J. Gee, K. W. Ignatoski, L. P. Kunju, A. Bucheit, H. J. Kintner, D. Morris, C. Tallman, J. Evron, C. G. Wood, et al.
Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression
Am. J. Pathol., March 1, 2010; 176(3): 1462 - 1468.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Mino-Kenudson, L. R. Chirieac, K. Law, J. L. Hornick, N. Lindeman, E. J. Mark, D. W. Cohen, B. E. Johnson, P. A. Janne, A. J. Iafrate, et al.
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Clin. Cancer Res., March 1, 2010; 16(5): 1561 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. A. Wainberg, A. Anghel, A. J. Desai, R. Ayala, T. Luo, B. Safran, M. S. Fejzo, J. R. Hecht, D. J. Slamon, and R. S. Finn
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Clin. Cancer Res., March 1, 2010; 16(5): 1509 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hammer, A. Sommer, I. Fichtner, M. Becker, J. Rolff, J. Merk, U. Klar, and J. Hoffmann
Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2010; 16(5): 1452 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. J. Boonstra, R. van Marion, D. G. Beer, L. Lin, P. Chaves, C. Ribeiro, A. D. Pereira, L. Roque, S. J. Darnton, N. K. Altorki, et al.
Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines
J Natl Cancer Inst, February 24, 2010; 102(4): 271 - 274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Chen, W. Lu, Y. Zheng, K. Gu, Z. Chen, W. Zheng, and X. O. Shu
Exercise, Tea Consumption, and Depression Among Breast Cancer Survivors
J. Clin. Oncol., February 20, 2010; 28(6): 991 - 998.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Moses, A. T. Paciorek, D. F. Penson, P. R. Carroll, and V. A. Master
Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE
J. Clin. Oncol., February 20, 2010; 28(6): 1069 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Moussavi, L. Fazli, H. Tearle, Y. Guo, M. Cox, J. Bell, C. Ong, W. Jia, and P. S. Rennie
Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice
Cancer Res., February 15, 2010; 70(4): 1367 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-P. Chang, S.-L. Yu, S.-Y. Lin, Y.-J. Hsiao, G.-C. Chang, P.-C. Yang, and J. J.W. Chen
Tumor Suppressor HLJ1 Binds and Functionally Alters Nucleophosmin via Activating Enhancer Binding Protein 2{alpha} Complex Formation
Cancer Res., February 15, 2010; 70(4): 1656 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Xie, C. Gore, J. Liu, R.-C. Pong, R. Mason, G. Hao, M. Long, W. Kabbani, L. Yu, H. Zhang, et al.
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis
PNAS, February 9, 2010; 107(6): 2485 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. R. Simon, F. Zhang, S. B. Soumerai, A. Ensroth, L. Bernstein, R. H. Fletcher, and D. Ross-Degnan
Failure of Automated Telephone Outreach With Speech Recognition to Improve Colorectal Cancer Screening: A Randomized Controlled Trial
Arch Intern Med, February 8, 2010; 170(3): 264 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. A. Tunio, A. Hashmi, and M. Rafi
Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials
Ann. Onc., February 5, 2010; (2010) mdq028v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Lonn, E. S. Gilbert, E. Ron, S. A. Smith, M. Stovall, and R. E. Curtis
Comparison of Second Cancer Risks from Brachytherapy and External Beam Therapy After Uterine Corpus Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 464 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. Liu, H. G. Vikis, Y. Lu, Y. Wang, A. G. Schwartz, S. M. Pinney, P. Yang, M. de Andrade, A. Gazdar, C. Gaba, et al.
Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 517 - 524.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Compr Canc NetwHome page
H. L. Kim, M. R. Puymon, M. Qin, K. Guru, and J. L. Mohler
A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death
J Natl Compr Canc Netw, February 1, 2010; 8(2): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 West J Nurs ResHome page
D. Wilkie, D. Berry, K. Cain, H.-Y. Huang, J. Mekwa, F. Lewis, B. Gallucci, Y.-C. Lin, A. C.-C. Chen, and N.-Y. Ko
Effects of Coaching Patients With Lung Cancer to Report Cancer Pain
West J Nurs Res, February 1, 2010; 32(1): 23 - 46.
[Abstract] [PDF]

Home page
 J Ultrasound MedHome page
A. Barua, P. Bitterman, J. M. Bahr, M. J. Bradaric, D. B. Hales, J. L. Luborsky, and J. S. Abramowicz
Detection of Tumor-Associated Neoangiogenesis by Doppler Ultrasonography During Early-Stage Ovarian Cancer in Laying Hens: A Preclinical Model of Human Spontaneous Ovarian Cancer
J. Ultrasound Med., February 1, 2010; 29(2): 173 - 182.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, A. A. Adjei, D. R. Gandara, K. L. A. Ziegler, P. J. Stella, K. M. Rowland Jr, S. E. Schild, et al.
Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study N0426
J. Clin. Oncol., February 1, 2010; 28(4): 614 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. F. Ferreira, R. A. de Oliveira, L. B. Jorge, W. C. Nahas, L. B. Saldanha, L. E. Ianhez, and M. Srougi
Urothelial carcinoma transmission via kidney transplantation
Nephrol. Dial. Transplant., February 1, 2010; 25(2): 641 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
C. L Roland, S. P Dineen, J. E Toombs, J. G Carbon, C W. Smith, R. A Brekken, and C. C Barnett Jr
Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts
Exp Biol Med, February 1, 2010; 235(2): 263 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. M. Hall, M. A. Barhoover, D. Kazmin, D. P. McDonnell, W. F. Greenlee, and R. S. Thomas
Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation
Mol. Endocrinol., February 1, 2010; 24(2): 359 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. K. Nagaraja, C. J. Creighton, Z. Yu, H. Zhu, P. H. Gunaratne, J. G. Reid, E. Olokpa, H. Itamochi, N. T. Ueno, S. M. Hawkins, et al.
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Mol. Endocrinol., February 1, 2010; 24(2): 447 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. C. Lim, K.-C. Chun, S.-J. Shin, I. H. Lee, K. T. Lim, C. H. Cho, S.-Y. Park, and J.-H. Nam
Clinical Presentation of Endometrioid Epithelial Ovarian Cancer with Concurrent Endometriosis: A Multicenter Retrospective Study
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 398 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
A. Razfar, B. F. Branstetter IV, A. Christopoulos, S. O. Lebeau, S. P. Hodak, D. E. Heron, E. J. Escott, and R. L. Ferris
Clinical Usefulness of Positron Emission Tomography-Computed Tomography in Recurrent Thyroid Carcinoma
Arch Otolaryngol Head Neck Surg, February 1, 2010; 136(2): 120 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
J. Fatima, T. Schnelldorfer, J. Barton, C. M. Wood, H. J. Wiste, T. C. Smyrk, L. Zhang, M. G. Sarr, D. M. Nagorney, and M. B. Farnell
Pancreatoduodenectomy for Ductal Adenocarcinoma: Implications of Positive Margin on Survival
Arch Surg, February 1, 2010; 145(2): 167 - 172.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Kassie, S. Kalscheuer, I. Matise, L. Ma, T. Melkamu, P. Upadhyaya, and S. S. Hecht
Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice
Carcinogenesis, February 1, 2010; 31(2): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Rineer, D. Schreiber, E. Katsoulakis, T. Nabhani, P. Han, C. Lange, K. Choi, and M. Rotman
Survival Following Sublobar Resection for Early-Stage Non-Small Cell Lung Cancer With or Without Adjuvant External Beam Radiation Therapy: A Population-Based Study
Chest, February 1, 2010; 137(2): 362 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. J. Wirth, A. M. Allen, M. R. Posner, R. I. Haddad, Y. Li, J. R. Clark, P. M. Busse, A. W. Chan, L. A. Goguen, C. M. Norris, et al.
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Ann. Onc., February 1, 2010; 21(2): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. Lei, E. M. Sturgis, Z. Liu, M. E. Zafereo, Q. Wei, and G. Li
Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck
Carcinogenesis, February 1, 2010; 31(2): 222 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Galanis, L. C. Hartmann, W. A. Cliby, H. J. Long, P. P. Peethambaram, B. A. Barrette, J. S. Kaur, P. J. Haluska Jr., I. Aderca, P. J. Zollman, et al.
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Cancer Res., February 1, 2010; 70(3): 875 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Hofland, W. M. van Weerden, N. F.J. Dits, J. Steenbergen, G. J.L.H. van Leenders, G. Jenster, F. H. Schroder, and F. H. de Jong
Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer
Cancer Res., February 1, 2010; 70(3): 1256 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Jia, Y. Gao, L. Wang, Q. Li, J. Zhang, X. Le, D. Wei, J. C. Yao, D. Z. Chang, S. Huang, et al.
Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity
Cancer Res., February 1, 2010; 70(3): 1111 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Logan-Collins, R. M. Thomas, P. Yu, D. Jaquish, E. Mose, R. French, W. Stuart, R. McClaine, B. Aronow, R. M. Hoffman, et al.
Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
Cancer Res., February 1, 2010; 70(3): 1130 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
X. Ma, Y. Park, S. T. Mayne, R. Wang, R. Sinha, A. R. Hollenbeck, A. Schatzkin, and A. J. Cross
Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH-AARP Cohort
Am. J. Epidemiol., February 1, 2010; 171(3): 312 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
C. Li, J. Lu, Z. Liu, L.-E. Wang, H. Zhao, A. K. El-Naggar, E. M. Sturgis, and Q. Wei
The Six-Nucleotide Deletion/Insertion Variant in the CASP8 Promoter Region Is Inversely Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Cancer Prevention Research, February 1, 2010; 3(2): 246 - 253.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
E. S. Kim, W. K. Hong, J. J. Lee, L. Mao, R. C. Morice, D. D. Liu, C. A. Jimenez, G. A. Eapen, R. Lotan, X. Tang, et al.
Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers
Cancer Prevention Research, February 1, 2010; 3(2): 148 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Keefe, M. A. Cohen, and M. S. Brose
Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
Clin. Cancer Res., February 1, 2010; 16(3): 778 - 783.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Boeck, M. Haas, R. P. Laubender, F. Kullmann, C. Klose, C. J. Bruns, R. Wilkowski, P. Stieber, S. Holdenrieder, H. Buchner, et al.
Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer
Clin. Cancer Res., February 1, 2010; 16(3): 986 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. V Krishnan and D. Feldman
Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment
Endocr. Relat. Cancer, January 29, 2010; 17(1): R19 - R38.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. E. Hung, M. A. Maricevich, L. G. Richard, W. Y. Chen, M. P. Richardson, A. Kunin, R. T. Bronson, U. Mahmood, and R. Kucherlapati
Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment
PNAS, January 26, 2010; 107(4): 1565 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-E Wang, Z. Hu, E. M. Sturgis, M. R. Spitz, S. S. Strom, C. I. Amos, Z. Guo, Y. Qiao, A. M. Gillenwater, J. N. Myers, et al.
Reduced DNA Repair Capacity for Removing Tobacco Carcinogen-Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics
Clin. Cancer Res., January 15, 2010; 16(2): 764 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. S. Finn
Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?
Clin. Cancer Res., January 15, 2010; 16(2): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Beleford, Z. Liu, R. Rattan, L. Quagliuolo, M. Boccellino, A. Baldi, J. Maguire, J. Staub, J. Molina, and V. Shridhar
Methylation Induced Gene Silencing of HtrA3 in Smoking-Related Lung Cancer
Clin. Cancer Res., January 15, 2010; 16(2): 398 - 409.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Rasool, W. LaRochelle, H. Zhong, G. Ara, J. Cohen, and E. C. Kohn
Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells
Clin. Cancer Res., January 15, 2010; 16(2): 600 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Du, S. M. Martin, M. Levine, B. A. Wagner, G. R. Buettner, S.-h. Wang, A. F. Taghiyev, C. Du, C. M. Knudson, and J. J. Cullen
Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer
Clin. Cancer Res., January 15, 2010; 16(2): 509 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L.-R. He, H.-Y. Zhao, B.-K. Li, L.-J. Zhang, M.-Z. Liu, H.-F. Kung, X.-Y. Guan, X.-W. Bian, Y.-X. Zeng, and D. Xie
Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients
Ann. Onc., January 11, 2010; (2010) mdp592v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo
Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram
J. Clin. Oncol., January 10, 2010; 28(2): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. F. Anderson, I. Jatoi, J. Tse, and P. S. Rosenberg
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
J. Clin. Oncol., January 10, 2010; 28(2): 232 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. J. Whitman, M. Pomerantz, Y. Chen, M. M. Chamberlin, B. Furusato, C. Gao, A. Ali, L. Ravindranath, A. Dobi, I. A. Sestrehenn, et al.
Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy
Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Jayachandran, W. J. Aronson, M. K. Terris, J. C. Presti Jr., C. L. Amling, C. J. Kane, and S. J. Freedland
Diabetes and Outcomes After Radical Prostatectomy: Are Results Affected by Obesity and Race? Results from the Shared Equal-Access Regional Cancer Hospital Database
Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 9 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. J. Langeberg, E. M. Kwon, J. S. Koopmeiners, E. A. Ostrander, and J. L. Stanford
Population-Based Study of the Association of Variants in Mismatch Repair Genes with Prostate Cancer Risk and Outcomes
Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 258 - 264.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D. Goss, A. Arnold, F. A. Shepherd, M. Dediu, T.-E. Ciuleanu, D. Fenton, M. Zukin, D. Walde, F. Laberge, M. D. Vincent, et al.
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
J. Clin. Oncol., January 1, 2010; 28(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
A. Hsu, T. M Bray, W. G Helferich, D. R Doerge, and E. Ho
Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells
Exp Biol Med, January 1, 2010; 235(1): 90 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang
A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer
Jpn. J. Clin. Oncol., January 1, 2010; 40(1): 10 - 16.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. R. Alexander Jr, D. L. Fraker, D. L. Bartlett, S. K. Libutti, S. M. Steinberg, P. Soriano, and T. Beresnev
Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters
J. Clin. Oncol., January 1, 2010; 28(1): 114 - 118.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. D. DuSell, E. R. Nelson, B. M. Wittmann, J. A. Fretz, D. Kazmin, R. S. Thomas, J. W. Pike, and D. P. McDonnell
Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators
Mol. Endocrinol., January 1, 2010; 24(1): 33 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
D. Y.C. Heng, C. Kollmannsberger, and K. N. Chi
Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
Therapeutic Advances in Medical Oncology, January 1, 2010; 2(1): 39 - 49.
[Abstract] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
A. K. Agarwala and N. H. Hanna
Review: Advanced non-small cell lung cancer: the role of maintenance therapy
Therapeutic Advances in Medical Oncology, January 1, 2010; 2(1): 17 - 23.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow All Versions of this Article:
CA.2007.0010v1
58/2/71    most recent
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS